Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
PHYSICIAN PERSPECTIVE - Viewpoint Based on the following articles: BJU Int 15 Oct 2010;Epub ahead of print, J Sex Med 2010;7(11):3725-35.
Canadian Data on Mild Erectile Dysfunction: Often an Early Sign of Vascular Disease
November 2010
INTRODUCTION Erectile dysfunction (ED) is both a common source of diminished quality of life (QoL) and a signal for potential serious underlying pathologies. Of these, impairment in blood flow secondary to progressive vascular disease is...
MEDICAL FRONTIERS - International Continence Society / International Urogynecological Association (ICS/IUGA)
Antimuscarinic Efficacy and Predictability in Overactive Bladder
Toronto, Ontario / August 23-27, 2010
Toronto - Symptoms of overactive bladder (OAB), which include urgency with or without incontinence, increased daytime frequency and nocturia, are very distressing. They affect quality of life and the ability to engage in physical...
PRIORITY PRESS - 26th International Papillomavirus Conference and Clinical and Public Health Workshops
Enhanced Treatment Strategies for External Genital Warts
Montreal, Quebec / July 3-8, 2010
It is estimated that approximately 75% to 80% of sexually active men and women have been exposed to genital human papillomavirus (HPV). Types 6 and 11 are the cause of most cases of genital warts (GW) worldwide (J Am Osteopath Assoc...
PRIORITY PRESS - 105th Annual Meeting of the American Urological Association
GnRH Antagonists: Advances in Androgen Deprivation Therapy for Prostate Cancer
San Francisco, California / May 29-June 3, 2010
San Francisco - GnRH agonists effectively suppress testosterone in over 90% of patients with advanced prostate cancer but can require as much as 30 days to achieve full suppressive effects, during which time testosterone levels actually...
PRIORITY PRESS - 25th Congress of the European Association of Urology
Androgen Deprivation Therapy in Prostate Cancer
Barcelona, Spain / April 16-20, 2010
Barcelona - New data have reinforced the utility of a gonadotropin-releasing hormone (GnRH) receptor blocker for slowing progression of advanced prostate cancer. Following a previous phase III study in which this agent compared favourably...
PRIORITY PRESS - 3rd World Congress on Controversies in Urology
An Enhanced Medical Approach to Androgen Suppression in Prostate Cancer
Athens, Greece / February 25-28, 2010
Athens - It has been 70 years since investigators first understood that prostate cancer is hormone-sensitive and that medical suppression of testosterone production can control the tumour and affect long-term disease outcomes. Yet there are...
PRIORITY PRESS - EUROGIN 2010 9th International Multidisciplinary Congress
Vaccination Against HPV Reduces Burden of Disease in Its Earliest Manifestations
Monte Carlo, Monaco / February 17-20, 2010
Monte Carlo - Many theoretical arguments have been raised in support of vaccination against human papillomavirus (HPV). Now, for the first time, compelling evidence that vaccination does reduce the earliest manifestations of infection in...
PRIORITY PRESS - Society of Urologic Surgeons of Ontario Meeting
Improving Survival in Prostate Cancer Through Enhanced Androgen Suppression
Toronto, Ontario / October 21, 2009
Toronto - Therapeutic options for the treatment of prostate cancer continue to expand, from orchiectomy, the first effective treatment, through to a variety of formulations of gonadotropin-releasing hormone (GnRH) agonists and now, more...
MEDICAL FRONTIERS - 64th Annual Meeting of the Canadian Urological Association
Prostate Cancer Risk Reduction with 5-alpha Reductase Inhibitors
Toronto, Ontario / June 28-July 1, 2009
Toronto - Research efforts continue to examine the possible role of risk reduction initiatives in prostate cancer and there have been several important new developments in the field. For example, recent analyses of the initial PCPT...